All In Biotech

Drug Trial Radar · NCT01650701

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.

Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,030 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,030

Actual

Start

Feb 2012

Primary completion

May 31, 2017

Study completion Apr 30, 2024

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Celgene Corporation
First posted
Jul 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length of your response (complete or partial response) compared to the standard of care rituximab chemotherapy treatment.

Conditions

  • Follicular Lymphoma

Interventions

  • RituximabDrug

    • Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • LenalidomideDrug

    • Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles

  • Rituximab - CHOPDrug

    six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles

  • Rituximab - CVPDrug

    eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,

  • Rituximab - BendamustineDrug

    six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. COMPLETE RESPONSE RATETime frame: Timeframe: CR/CRu rate at 120 weeks
  2. Progression Free Survival (PFS)Time frame: up to 13 years

Locations

35 sites in 8 countries. Site status is shown where the registry gives one.

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Nepean Hospital

    Penrith, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • CHU Mont-Godinne

    Yvoir, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Fraser Valley Cancer Centre

    Surrey, British Columbia, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Moncton Hospital

    Moncton, New Brunswick, Canada

  • Atlantic Health Sciences Corp - Saint John Regional Hospital

    Halifax, Nova Scotia, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • UHN-Princess Margaret Hospital

    Toronto, Ontario, Canada

  • CHUM Hopital Notre-Dame

    Montreal, Quebec, Canada

  • McGill University Department of Oncology

    Montreal, Quebec, Canada

  • Hôpital de l'Enfant-Jesus, CHU de Quebec

    Québec, Quebec, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

  • CHU Claude Huriez

    Lille, France

  • LMU Munchën - Klinikum Grosshadern

    München, Germany

  • Medizinische Klinik der Universität Tübingen

    Tübingen, Baden-Wurttemberg, Germany

  • Uniklinik Köln

    Cologne, Nordrhein, Germany

  • Policlinico Sant'Orsola-Malpighi

    Bologna, Italy

  • Sant'Andrea Hospital

    Rome, Lazio, Italy

  • Instituto Português Oncologia

    Lisbon, Portugal

  • Hospital Clínico de Barcelona

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Vall d´Hebron

    Barcelona, Spain

  • Institut Català d'Oncologia de Girona (ICO Girona)

    Girona, Spain

  • Hospital Ramon y Cajal

    Madrid, Spain

  • Hospital Costa del Sol

    Marbella, Spain

  • Hospital Universitario Salamanca

    Salamanca, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain

  • Hospital Virgen del Rocio

    Seville, Andaloucia, Spain

  • Hospital Universitario Mutua de Terrassa

    Terrassa, Barcelona, Spain

  • Hospital Universitario de Canarias

    Santa Cruz de Tenerife, Canary Islands, Spain

  • Hospital Son Llatzer

    Palma, Mallorca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.